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Abstract: Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth
leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy,
and/or long-term androgen deprivation therapy are the recommended treatment options. However,
subsequent progression to metastatic disease after initial therapy results in low 5-year survival rates (29%).
Omics technologies enable the acquisition of high-resolution large datasets that can provide insights into
molecular mechanisms underlying PCa pathology. For the purpose of this article, a systematic literature
search was conducted through the Web of Science Database to critically evaluate recent omics-driven
studies that were performed towards: (a) Biomarker development and (b) characterization of novel
molecular-based therapeutic targets. The results indicate that multiple omics-based biomarkers with
prognostic and predictive value have been validated in the context of PCa, with several of those being
also available for commercial use. At the same time, omics-driven potential drug targets have been
investigated in pre-clinical settings and even in clinical trials, holding the promise for improved clinical
management of advanced PCa, as part of personalized medicine pipelines.
Keywords: biomarkers; drug targets; omics; prostate cancer
1. Introduction
Prostate cancer (PCa) is placed second among the most frequently diagnosed cancers in males
worldwide [1], affecting approximately one out of nine men during their lifetime [2]. In 2018,
over 1.2 million men were diagnosed with PCa worldwide [3], ranking this malignancy as the one
with the highest incidence among men in 114 countries and the first cause of cancer related deaths
in 56 countries [4]. Unfortunately, there is a treatment paradox regarding PCa. On the one hand,
more than 40% of the PCa patients experience slow-growing cancer forms (with local and regional
cancer spread), for whom the 5-year survival rate is almost 100% [5]. For such patients, curative options
do exist, but patients with indolent clinically insignificant PCa are frequently overtreated. On the
other hand, the same malignancy is regarded as not curable at an advanced stage. For advanced PCa,
radical prostatectomy (RP), radiotherapy, and/or long-term androgen deprivation therapy (ADT) are
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the recommended treatment options as part of multi-modal therapy [6]. Yet, after resistance to ADT,
PCa progresses to metastatic castration resistant PCa (mCRPC), and treatment options are limited.
As a result, the 5-year survival prognosis is reduced to 29% [5].
Clinical practice for monitoring PCa progression and metastasis is currently based on imaging
techniques, such as bone scans, computed tomography (CT), magnetic resonance imaging (MRI) scans,
and the recently introduced prostate-specific membrane antigen imaging positron emission tomography
(PSMA PET-CT), which are typically performed after a raise in PSA levels. Nevertheless, although PSMA
PET-CT has demonstrated superior sensitivity for detecting lymph node cancer spread, its potential
impact on clinical management is still under evaluation [7]. Considering these clinical challenges,
prognostic biomarkers for monitoring PCa recurrence and/or metastasis are necessary. Upon PCa
recurrence and progression, and as the prognosis worsens, several second line treatment options are
available, including taxane-based chemotherapy (like cabazitaxel or docetaxel), agents targeting the
androgen receptor (AR), such the AR antagonists enzalutamide, apalutamide, darolutamide, and the
cytochrome P450 inhibitor abiraterone acetate, immunotherapy (sipuleucel-T and immune checkpoint
inhibitors), radiotherapy (including radium-223 and Lu-177-PSMA-617) [2], and the recently approved
targeted therapies to inhibit poly (adenosine diphosphate-ribose) polymerase (PARP) such as olaparib,
niraparib, and rucaparib. Yet, the response rates to the above therapies are low and so is the overall
survival for these patients. Considering the heavy burden of advanced PCa, novel, more specific
treatments based on interpretation of omics findings are expected to be of high value, along with effective
tools to predict and monitor treatment response and guide individualized intervention for mCRPC.
Omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics/
lipidomics have facilitated simultaneous analysis of thousands of molecular features, resulting in a better
definition of molecular pathophysiology in chronic heterogeneous diseases, like cancer [8]. As a result,
various clinically relevant actionable mutated genes, disease-altered pathways, and molecular patterns
with prognostic and predictive significance were introduced, giving rise to personalized medicine
approaches [9]. For advanced PCa in particular, molecularly driven drug targets are expected to improve
intervention, as part of tailored treatment strategies based on novel more specific therapies, guided by
omics-based biomarkers. The two pipelines for omics-driven personalized intervention in advanced PCa
are schematically presented in Figure 1. Considering these two directions, for the purpose of this review,
a systematic literature search was conducted using the Web of Science database to critically evaluate
recent omics studies focusing on: a) Biomarker development and b) introduction and verification of
potential drug targets. Overall, this review aims to critically present the omics-driven studies and assess
their clinical implementation potential in advanced PCa.
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Figure 1. Directions of omics-driven studies towards personalized intervention for advanced prostate
cancer (PCa). This figure has been adapted from [10] with permission.
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2. Literature Search and Review Strategy
A systematic literature search was performed through the Web of Science search platform on
15 July 2020. Published reports were retrieved from Web of Science Core Collection based on the following
search terms: (1) TOPIC: (“omic*” or “proteom*” or “transcriptom*” or “genom*” or “metabolom*”)
AND TOPIC: (“prostate ca*” or “prostate adeno*”) AND TOPIC: (“drug” or “therap*” or “biomarker*” or
“marker*”) and (2) Timespan: 2015–2020. The above search resulted in the retrieval of 3035 manuscripts.
The manuscripts were further shortlisted based on the number of citations, as follows: A threshold of
≥20 was applied for the years 2015, 2016, 2017, and 2018. A citation threshold of ≥10 was applied for
manuscripts published in year 2019, and no citation threshold was applied for articles published in
year 2020. Shortlisting based on the number of citations resulted in 998 selected manuscripts (Table S1).
These 998 manuscripts were subsequently screened for their relevance in the field of omics-derived
biomarkers and/or potential drug targets in prostate cancer. Methodological papers, papers presenting
databases and web-based tools, reviews, opinion articles, commentaries, conference and case reports
were excluded, as well as manuscripts referring to different malignancies (n = 575 articles). As a
result, 423 shortlisted original manuscripts were further screened based on the following criteria:
(a) Investigation of advanced PCa pathology; (b) reporting on relevant clinical endpoints (i.e., prediction
of metastasis, biochemical recurrence, overall survival, prediction of treatment of advanced PCa);
(c) application of at least one omics platform; and (d) investigation in human specimens (excluding
studies performed only in cell lines and/or animal models). After thorough screening, 56 studies
were selected and presented in this review (Table S2), based on agreement between two independent
evaluators (co-authors). A graphical representation of the search and review strategy is presented in
Figure 2.
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3. Molecular Landscape of Localized and Advanced Prostate Cancer
3.1. Molecular Subclassification of PCa Tumours
Several large omics datasets, including genomes [11–13], mitochondrial genomes [12],
transcriptomes [12], methylation datasets [12,13], and proteogenomic datasets [14,15] that were
acquired through omics analysis of PCa tumors, are available via large scientific networks and
research consortia. Comprehensive analysis of the above datasets revealed a plethora of molecular
alterations that have been reported in PCa, all indicating a significant inter-patient heterogeneity
within the PCa tumors. Among the most prominent molecular alterations, oncogene amplifications
in AR gene, MYC proto-oncogene, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha (PIK3CA) gene were reported. Additionally, frequent mutations were evident in
tumor suppressor genes like phosphatase and tensin homolog (PTEN), the gene encoding tumor
protein p53 (TP53), and prostatic tumor suppressor Homeobox protein Nkx-3.1 (NKX3-1). In parallel,
oncogenic gene fusions were characterized, including the fusion of the androgen regulated erythroblast
transformation-specific (ETS)-related gene (ERG) with the gene encoding for transmembrane protease
serine 2 (TMPRSS2). Furthermore, additional point mutations were identified in PCa tumors involving
speckle type BTB/POZ protein coding gene (SPOP) and forkhead Box A1 (FOXA1), as well as multiple
AR splice variants (like AR-V7 and AR-V9).
In one of the most comprehensive molecular analyses reported by the Cancer Genome Atlas project
(TCGA) [13], 333 primary PCa tumors were profiled for somatic copy number variations, methylation,
transcript levels, and microRNAs, and were further complemented with protein data (through reverse
phase protein arrays) [13]. As a result, a molecular taxonomy of PCa was proposed, presenting
seven main subtypes, into which 74% of the PCa primary tumors could be classified. Moreover,
molecular changes in several interlinked pathways, like signaling and DNA damage repair pathways,
were reported [13]. The majority of tumors (59%) were enriched in gene fusions of the ETS family
and were classified into the first four classes: Gene fusions of ERG (46%), ETS variant transcription
factor (ETV) 1 (8%), ETV4 (4%), and follicular lymphoma susceptibility to 1 (FL1; 1%). The ERG
gene fusions were observed together with androgen regulated partner genes, most frequently with
TMPRSS2, but also with solute carrier family 45 member 3 (SLC45A3) and NDRG1 gene. Furthermore,
ETS positive tumors were identified harboring PTEN deletions [13]. The second most frequent observed
subclass of tumors was characterized by the presence of mutations in the SPOP gene (11%), followed
by classes carrying mutations in FOXA1 (3%), and isocitrate dehydrogenase 1 (IDH1; 1%) genes.
The SPOP-mutant class was additionally characterized by deletions of chromodomain helicase DNA
binding protein 1 (CHD1), 6q, and 2q. SPOP mutations were reported to deregulate AR and AR
coactivators, leading to increased AR activity. Additional molecular analysis revealed that, regardless
of the above seven subclasses, 25% of the prostate cancers harbored mutations in genes involved
in kinase signaling pathways, such as PI3K or mitogen-activated protein kinase (MAPK) pathways,
and 19% of the PCa tumors harbored inactivating mutations in DNA repair genes [13].
Complementary analysis by comprehensive integration of proteomics and genomics datasets
indicated that tumors characterized by ETS fusions presented an extensive dysregulation of downstream
metabolic pathways [14]. Similar to this observation, in a proteomics study including high-resolution
proteomics on tissue specimens from 22 PCa patients, Latosinska et al., reported on 1433 proteins,
out of which, 145 were significantly altered in advanced PCa. Downstream functional enrichment
analysis revealed alterations in several metabolic pathways, metabolism, and signaling, including
among others protein interactions between MYC targets [16].
3.2. Molecular Evolution of Metastatic Disease
In an integrative analysis aiming to characterize the molecular landscape of metastatic PCa in
comparison to primary tumors [17], whole exome sequencing of 150 mCRPC tumors was performed.
The analysis revealed alterations in AR, TP53, PTEN, and ETS genes at high frequency (40–60%).
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When comparing the mCRPC exome profiles with those from primary tumors (n = 440; TCGA dataset),
TP53 and AR mutations were enriched, together with alterations in DNA damage repair related genes
[like breast cancer type 1 and 2 susceptibility genes (BRCA1, BRCA2) and ataxia telangiectasia-mutated
gene (ATM)]. In parallel, there was a complete absence of IDH1 mutations in metastatic tumors.
Compared to primary PCa, mCRPC tumors showed higher overall burden in copy number variations
and point mutations in the PI3K pathway, but also more frequent amplification and/or mutation of
AR signaling in metastatic tumors [17]. Towards that end, a longitudinal genomics study including
176 primary and metastatic PCa tumors derived from the same individuals (n = 63) was conducted.
Whole exome sequencing, microarray hybridization, and copy number variation analyses in the above
cohort confirmed previous findings on recurrent alterations in AR, ERG, TP53, and SPOP genes.
The analysis additionally supported high inter-patient, but relatively low intra-patient, heterogeneity
in relation to the genomic events [18], further suggesting a clonal evolution of metastatic disease.
This phenomenon is even more prominent in untreated patients with advanced PCa, where the large
majority of driver gene mutations were common between primary and metastatic PCa tumors within
individual patients, suggesting low intra-patient heterogeneity [19]. In the above study, whole exome
and whole genome sequencing profiles were analyzed from 20 treatment-naïve patients and 76 untreated
metastases. The detected alterations were further mapped into phylogenetic trees to determine timing
and evolution of mutational landscape. Based on this analysis, evidence from untreated patients
demonstrates that driver mutations promote metastasis seeding, with increased heterogeneity in slower
growing primary tumors. This is in contrast to driver mutations that result in fast metastasis and are
correlated with lower intra-patient heterogeneity, as metastasis occurs before different driver subclones
are expanded [19]. Genomic evolution of metastasis was more precisely investigated by employing
phylogenetic analysis, in a cohort of 51 tumors derived from 10 patients that were analyzed via whole
genome sequencing. The results of this study supported that metastatic evolution related to castration
resistance is based on clonal seeding of the cells from the primary tumor, with whom there is a common
genetic imprint [20]. The clonal seeding is a result of the tumor′s requirement to overcome androgen
deprivation, which consequently results in multiple resistant subclones [20]. Additionally, mutations in
TP53 and DNA damage repair genes have been identified as driver mutations in PCa metastasis.
This scientific evidence supports previous reports [21], which have suggested a higher overall burden
of mutations in DNA repair and other signaling pathways in metastatic PCa tumors.
3.3. Molecular Classification of Rare Prostate Tumours
Characterization of PCa at the molecular level has additionally enabled a better understanding
of rare aggressive PCa clinical phenotypes, such as small cell prostate carcinoma (SCPC) with
neuroendocrine differentiation. Neuroendocrine prostate cancers (NEPC) frequently present an
aggressive phenotype [22] and typically do not respond to ADT [22,23]. In a prospective study
including 202 PCa patients who progressed after abiraterone or enzalutamide treatment, 17% were
characterized with SCPC phenotype (exhibiting neuroendocrine features) [23]. This group of patients
experienced decreased overall survival (OS) after ADT [hazard ratio (HR) of 2.02; p = 0.027]. Genomics
analysis in the above cohort revealed that in the SCPC tumors, mutations in genes related to DNA repair
pathway, such as in BRCA1, BRCA2, ATM, cyclin-dependent kinase 12 (CDK12), partner and localizer of
BRCA2 (PALB2), fanconi anaemia, complementation group A (FANCA), checkpoint kinase 2 (CHEK2),
mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), MSH3, MLH3, and MSH6 were less frequent
compared to the rest cohort (p = 0.035). Instead, prominent alterations in SCPC tumors included
amplification of AR gene supported by strong nuclear staining (assessed by immunohistochemistry),
frequent loss of TP53 and retinoblastoma protein 1 (RB1), likely as a result of treatment selective pressure
related to androgen antagonists. Additional alterations included upregulation of E2F1 transcription
factor, overexpression of DEK proto-oncogene (E2F target), and upregulation of pancreatic and
duodenal homeobox 1 (PDX1), a Hox-type transcription factor, which promotes neuroendocrine
differentiation in the pancreas [23].
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In a similar study, whole exome sequencing in 32 PCa patients revealed serine/arginine repetitive
matrix 4 (SRRM4) splicing factor as a master regulator of >66% of downstream events that drive
neurogenesis, through targeting RE1 silencing transcription factor (REST) and enhancing loss of
function of TP53 [22]. Similarly, in a study employing copy number variation analysis in tumors
from 59 PCa patients, SCPC tumors revealed RB1 loss, TP53 mutations, amplification of aurora kinase
A gene (AURKA) and N-Myc proto-oncogene (MYCN), as well as expression of luminal epithelial
markers and proneural transcription factors [24]. MYCN is an oncogenic transcription factor that has
been reported to promote neural lineage gene expression in PCa [25]. MYCN is stabilized by AURKA,
which prevents MYCN degradation in SCPC (and other malignancies with neuronal differentiation).
Among others, MYCN promotes tumor aggressiveness by driving AR independence. Based on this
important molecular finding, a clinical trial has been initiated, using the AURKA inhibitor alisertib to
disrupt the stabilized complex with MYCN. In this phase 2 clinical trial, patients with AR-independent
neuroendocrine PCa were treated with alisertib. Genomic analysis confirmed mutations in RB1 (55%),
TP53 (46%), PTEN (29%), and AR (27%). However, while patients with AURKA mutations showed
increased OS after treatment with alisertib, the difference was not significant (p = 0.05).
Along these lines, following the observations that advanced prostate cancer shares multiple
characteristics with stem cells, such as self-renewal and proliferative capacity, tumor-associated calcium
signal transducer 2 (TROP2) was identified as a master regulator of prostate stem cell self-renewal [26]
also contributing to the neuroendocrine phenotype in CRPC. Based on immunohistochemical analysis
in 58 recurrent and 176 non recurrent PCa patients, TROP2 was identified as highly expressed in
recurrent PCa and significantly correlated with biochemical recurrence over a period of nine years
(BCR; p < 0.05) [27]. Thorough investigation at the pre-clinical setting also revealed that TROP2 mediated
neuroendocrine differentiation, was additionally accompanied with significant downregulation of
AR pathway and concomitant upregulation of PARP1. Based on these findings, a clinical trial testing
sacituzumab govitecan, an antibody-drug conjugate targeting TROP2 positive cells, has been recently
initiated for patients with mCRPC, who have progressed after abiraterone or enzalutamide treatment
(NCT03725761). Although TROP2′s association with neuroendocrine phenotype in CRPC, was not
derived from a pure omics investigation, the above trial was included as relevant to the context based
on the reviewer′s recommendation.
4. Omics-Derived Biomarkers Predictive of Clinical Outcome and Treatment Response
4.1. Commercially Available Omics-Driven Biomarker Tests with Diagnostic Potential
Comprehensive molecular analysis applying the various omics platforms improved our
understanding of molecular mechanisms underlying PCa pathology and offered a plethora of potential
diagnostic, prognostic, and predictive biomarkers. As a result, several molecular based tests are
currently available, aiming at improving on PCa clinical management [28]. These omics-driven
tests include diagnostic biomarkers for PCa early detection and guiding biopsies. As this review
focuses on advanced PCa, these tests are outside the scope of this article, and thus are only briefly
described. Prostate cancer antigen (PCA3) or DD3 is a long non-coding RNA, and the first molecular
urine-based assay that was approved by the U.S. Food and Drug Administration (FDA) for reducing
unnecessary biopsies in a repeated biopsy setting [29,30]. PCA3 urinary testing, resulted in 67%
sensitivity and 83% specificity for detection of PCa [31], while in the repeated biopsy setting PCA3
demonstrated sensitivity estimates in the range of 52–58% and specificity in the range of 72–87%,
respectively [29,30]. Additional available tests based on omics biomarkers are the SelectMDx test,
the Mi-Prostate Score, and the ExoDx Prostate Intelliscore. The selectMDx assay is based on the
combination of two mRNA biomarkers (transcripts), homeobox protein (DLX-1), and homeobox
protein Hox-C6 (HOXC6). SelectMDx resulted in an area under the curve (AUC) of 0.73 for detecting
high grade PCa [Gleason score (GS) ≥ 7] [32]. Upon integration of the two molecular biomarkers with
clinical variables (DRE, PSA density, and number of previous biopsies) the AUC estimate was improved
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to 0.89 [32]. Mi-Prostate Score (Michigan Prostate score/MiPS) refers to the combination of PCA3 long
non-coding RNA with the gene fusion TMPRSS2-ERG that is described above and has been extensively
studied though genomics studies in PCa progression [33]. The combined omics-based test in the form
of a nomogram (Mi-Prostate Score) resulted in AUC estimates of 0.76 and 0.78 for detecting any PCa
and high grade (GS ≥ 7) PCa, respectively [33]. ExoDx Prostate Intelliscore is a three-gene biomarker
test based on the exosomal transcript levels of PCA3, ERG, and SAM pointed domain-containing
Ets transcription factor (SPDEF). Combination of the above transcripts (i.e., the ExoDx Prostate
Intelliscore) has been introduced to guide first biopsy [34] and resulted in an AUC of 0.71 [34].
An additional tissue-based assay called ConfirmMDx is also available, targeting epigenetic alterations
(methylation) of promoter regions of Ras association domain-containing protein 1 (RASSF1), glutathione
S-transferase pi gene (GSTP1), and adenomatous polyposis coli protein (APC) [35]. ConfirmMDx was
developed with the intended application to reduce unnecessary repeated biopsies, demonstrating
sensitivity and specificity estimates of 62% and 64%, respectively [35]. Following the same principle,
DNA methylation particularly at targeted genes like GSTP1, cyclin-dependent kinase inhibitor 2A
(CDKN2A), DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), secretoglobin family 3A member
1 (SCGB3A1), and hypoxia-inducible factor 3 alpha (HIF3A), has been previously investigated in
the context of PCa [36,37]. Most recently, published data including a genome-wide analysis in
79,194 prostate cancer patients revealed 759 CpG sites (corresponding to 82 genomic loci significantly
associated with PCa risk; showing false discovery rate adjusted by Bonferroni correction; p≤ 6.47× 10−7).
Out of those, 42 CpG sites were also correlated with altered expression of 28 target genes, 11 of which
were subsequently validated in the TCGA cohort. Among the most promising genes altered, as a
result of the CpG methylation, were nuclear ubiquitous casein and cyclin-dependent kinases substrate
[NUCKS1; odds ratio (OR) of 1.35; p = 3.59 × 10−5], complement C4B gene (OR of 0.79; p = 2.18 × 10−4),
cilia and flagella associated protein 44 (CFAP44; OR of 1.91; p = 9.11 × 10−14) [38]. Yet, validation of the
above methylation targets in the appropriate clinical setting is required to demonstrate potential value
as markers for PCa risk.
4.2. Prognostic Biomarkers for Advanced PCa
4.2.1. Genomics Based Biomarker Tests
In the context of advanced PCa, molecularly based prognostic tools, predictive of PCa clinical
outcome, are highly relevant. Among those, most studied commercially available gene panels for
prediction of PCa outcome are: (a) Decipher, (b) Oncotype DX Genomic Prostate Score, and (c) Prolaris.
All three gene-based prognostic biomarker tests are currently applied to predict disease outcomes
in addition to clinical parameters or clinical nomograms [28]. Decipher is based on 22 coding and
non-protein coding regions, which was developed based on post-operative tissue specimens from PCa
patients who had undergone RP [39]. The intended context was to predict metastasis after RP [40,41]
based on scientific evidence for significant prediction of metastasis after biochemical recurrence [hazard
ratio (HR) of 1.37; p = 0.018] [42–44] and prediction of disease specific mortality (HR of 1.57; p = 0.037).
Follow-up studies demonstrated that Decipher is an independent significant predictor of 5-year
metastasis (OR of 1.48; p = 0.018) after adjusting for clinical risk factors, outperforming similar models
(like Stephenson nomogram and CAPRA-S) [45]. Similarly, OncotypeDX is a 17-gene assay which is
based on the detection of 12 prostate cancer related genes, encoding for zincα 2-glycoprotein 1 (AZGP1),
kallikrein-2 (KLK2), 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2), protein FAM13C (FAM13C),
filamin-C (FLNC), gelsolin (GSN), tropomyosin beta chain (TPM2), glutathione S-transferase Mu 2
(GSTM2), targeting protein for Xklp2 (TPX2), biglycan (BGN), collagen alpha-1(I) chain (COL1A1),
secreted frizzled-related protein 4 (SFRP4), and five other reference genes. As part of investigations in
advanced PCa, the above genomic score proved as a significant predictor of biochemical recurrence
following RP (OR of 2.9; p < 0.001) [46,47] and predictor of metastasis (OR of 2.8; p < 0.001) [48].
Furthermore, the Prolaris test, a cell cycle progression test that is based on 46 genes, has been introduced
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as a tool to predict biochemical recurrence (BCR) based on RP tissue gene expression analysis [49,50].
The Prolaris test was able to predict BCR in PCa patients monitored for up to 72 months (HR of 1.44;
p = 5.3 × 10−4) [50]. Unfortunately, a comparison of these 3 tests in the same cohort and consequently
an assessment of potential additive value is not available yet. Moreover, prediction is ultimately only
of value if it meets a consequence: Targeted therapeutic intervention. Unfortunately, to the best of our
knowledge, a study investigating a benefit of intervention as a result of any of the predictive tests is
still missing.
4.2.2. Biomarker Tests Targeting Non-Coding RNAs
Applying advanced genomic methods revealed that 66% of the genome is actively transcribed into
noncoding RNAs (ncRNAs), while less than 2% of the sequences encode proteins [51,52]. ncRNAs are
further categorized according to their length into: (a) Short and medium ncRNAs such as microRNAs
(miRNAs), small nucleolar RNAs (snoRNAs), piwi interacting RNAs (defined based on their interaction
with piwi subfamily Argonaute proteins [53]), and (b) long non-coding RNAs (lncRNAs). Both short
and medium, as well as long non-coding RNAs, have been implicated in cancer initiation and
progression [54].
In PCa in particular, apart from PCA3 or DDR, several other lncRNAs have been reported to be
associated with advanced PCa, such as SWI/SNF complex antagonist associated with prostate cancer 1
(SChLAP1), nuclear enriched abundant transcript 1 (NEAT1), prostate-specific transcript 1 (PCGEM1),
prostate cancer associated non-coding RNA 1 (PRNCR1), HOTAIR long noncoding RNA and prostate
cancer associated transcript 1 (PCAT1) [55]. The most promising potential as a prognostic biomarker
has been demonstrated for SChLAP1 (lncRNA), specifically implicated in advanced PCa and reported
as significant predictor of PCa 10 year metastasis (OR of 2.45; p < 0.0001) [56]. A further lncRNA,
prostate cancer associated transcript 14 (PCAT14), was investigated for its potential as a prognostic PCa
biomarker. Following an integrative analysis of RNA sequencing data (n = 58 primary PCa tumors)
with Affymetrix datasets from 131 primary and 19 metastatic PCa tumors, PCAT14 was identified as
significantly downregulated in metastatic PCa [57]. Patients with high PCAT14 expression showed
increased metastasis free survival (HR of 0.66; p = 0.023), overall survival (HR of 0.71; p = 0.0044),
and disease specific survival (HR of 0.54; p = 0.023) [57].
Along these lines, miRNAs have also been reported as potential prognostic biomarkers predicting
clinical outcome of advanced PCa. MiR-221 and miR-222 were observed as downregulated in
PCa as part of a tumor suppressor cluster [58]. Evidence based on molecular biology suggested
that re-establishment of expression levels of both miRNAs inhibits cell migration and invasion.
MiR-222, additionally demonstrated potential as a prognostic marker and independent predictor
of progression-free survival in CRPC patients (HR of 0.21; p = 0.006) [58]. Similarly, screening of
752 miRNAs for significant correlations with PCa led to the identification of a three microRNA-based
prognostic biomarker including miR-185-5p, miR-221-3p, and miR-326. This microRNA biomarker
panel demonstrated a prognostic potential for predicting BCR of PCa (HR of 1.36; p = 0.031) in three
RP cohorts over a time span of 120 months [59].
4.2.3. Biomarker Tests Targeting Proteomics Features
A study employing high resolution proteomics analysis by mass spectrometry was performed in
28 prostate tumors from formalin-fixed paraffin-embedded prostatectomy samples [15]. Increased
expression of proteins involved in multiple metabolic processes was detected, like fatty acid and
protein synthesis, ribosomal biogenesis, and protein secretion, among others including carnitine
palmitoyltransferase 2 (CPT2, fatty acid transporter), coatomer protein complex, subunit alpha (COPA,
vesicle secretion), and mitogen- and stress-activated protein kinase 1 and 2 (MSK1/2, protein kinase).
Additionally, proneuropeptide-Y (pro-NPY) was found overexpressed in PCa and was further correlated
with lower PCa specific survival (HR 2.13; p = 0.0087) [15]. Moreover, starting from a proteomics
discovery study including 381 PCa patients and by employing quantitative multiplex proteomics
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imaging, 12 protein biomarkers including actinin Alpha 1 (ACTN1), cullin 2 (CUL2), derlin 1 (DERL1),
fusion RNA-binding protein FUS/TLS (FUS), mitochondrial 70 kDa heat shock protein (HSPA9),
decaprenyl-diphosphate synthase subunit 2 (PDSS2), zinc finger protein PLAG1 (PLAG1), phospho-S6
Ribosomal Protein (pS6), mothers against decapentaplegic homolog 2 (SMAD2), mothers against
decapentaplegic homolog 4 (SMAD4), voltage-dependent anion-selective channel 1 (VDAC1), and Y
box binding protein 1 (YBX1), were identified as significantly correlated with PCa outcome [60].
Subsequently, eight of the above biomarkers (DERL1, PDSS2, pS6, YBX1, HSPA9, FUS, SMAD4, CUL2)
demonstrated significant prognostic values when correlated with disease pathology and were further
considered as an 8-biomarker panel. The latter was further validated in an independent cohort of
276 patients, demonstrating significant correlation in predicting aggressive non-localized >T3a or N+
or M+ PCa [60]. Unfortunately, no HR or significance measures were reported. While not investigating
advanced PCa, in a recent paper, multiple urinary peptide based biomarkers were described as a result
of investigating samples from 823 patients with different grades of PCa [61]. Nineteen endogenous
peptides derived from different collagen chains, from fractalkine, semaphorin-7A, and from Protein
phosphatase 1 regulatory subunit 3A were combined into a classifier using support vector machines.
In an independent test set, this classifier could distinguish patients GS ≥ 7 with an AUC of 0.81
(p < 0.0001). Especially considering the ease and non-invasive procedure of sampling (urine) compared
to the tissue-based biomarkers described above, further investigation of this classifier for its ability to
predict progression to CRPC and mCRPC appears warranted.
4.3. Predictive Biomarkers for Advanced PCa
4.3.1. Circulating Tumor Cells as Predictive Biomarkers to Taxane Chemotherapeutic Agents
There is an emergent need for biomarkers to predict response to available treatments in patients
with advanced PCa, especially those with CRPC. Towards this goal, several omics-driven studies
have been published mainly investigating circulating tumor cells (CTCs) and cell-free DNA (cfDNA)
extracted from serum. cfDNA concentration was evaluated as predictive biomarker in patients receiving
taxane-based chemotherapy, as part of two phase 2 clinical trials, including more than 2300 CRPC
patients. In the above trials, the patients received chemotherapy as first line treatment (n = 777 treated
with cabazitaxel and n = 391 with docetaxel) and those receiving chemotherapy as second-line treatment
(n = 1200 treated with cabazitaxel). In the pooled analysis, including 2368 patients, the baseline cfDNA
concentration correlated with shorter progression free survival (PFS) (HR of 1.54; p = 0.004), and shorter
OS after taxane-based chemotherapy (HR of 1.53, p = 0.001) in both first- and second-line chemotherapy
settings [62]. The above results demonstrated a good predictive potential of cfDNA levels for predicting
response to taxane-based chemotherapy [62].
4.3.2. Androgen Receptor Expression as Predictive Biomarker to AR Targeted Therapies
Molecular characterization of progression CPRC has revealed evolution to an AR- independent
phenotype and, as described above, neuroendocrine tumor characteristics. As these types of tumors do
not respond to AR-targeted treatments, such patients could potentially benefit from alternative treatment
like chemotherapy and/or PARP inhibitors. As such, non-invasive detection of neuroendocrine
transition could be applied as a stratification tool to stratify patients for AR-targeted therapies [63]. In a
proof-of-concept prospective study including 27 CRPC patients (12 with neuroendocrine phenotype
and 15 with atypia), CTCs were extracted and characterized via an immunofluorescence platform
(Epic) demonstrating unique morphological and cell surface markers. Lower AR expression and lower
cytokeratin expression was detected in NEPC compared to CTCs from all other CRPC patients [63].
The unique CTC markers indicating NEPC phenotype (such as cytokeratin, CD45, CD56) were
subsequently selected to train a random forest classifier to detect neuroendocrine phenotype. This panel
was further validated in an independent prospective cohort of 159 CRPC patients. Based on the
classification, 17 out of 159 (10.7%) CRPC patients were classified with neuroendocrine phenotype
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based on the CTC markers. In these 17 patients a small, yet significantly higher proportion of visceral
metastases (p = 0.04) was detected [63]. These results indicate that characterization of neuroendocrine
specific CTCs in the CRPC setting might be a useful tool to stratify patients for AR-targeted therapies.
However, a clinical study investigating such an approach is missing.
In a similar study, serum cfDNA [64] was investigated with the aim to evaluate circulating AR
copy number as a predictive marker for CRPC patients treated with enzalutamide after chemotherapy
(docetaxel) [64]. The serum circulating AR copy number was assessed in a prospective cohort of 59 CRPC
patients at the baseline and correlated with progression free (PFS) and OS. AR copy number gain was
detected in 21 (36%) patients, which was further correlated with worse outcome, significantly lower PFS
(2.4 vs. 4.0 months, p = 0.0004), and OS (6.1 vs. 14.1 months, p = 0.0003). More recently, a prospective
multi-omics study was conducted by integrating cf-DNA and cf-RNA datasets from 67 mCRPC patients
that receive AR antagonists (n = 41) or taxane-based chemotherapy (n = 26), assessing molecular
alterations related to AR gene [65]. Copy number variations in AR and other somatic mutations
(assessed based on cfDNA profiles) were studied, along with AR-variants (AR-V7 and AR-V9 based
on cfRNA profiles) providing significant evidence that AR gain and presence of any AR alteration
predicted reduced progression-free survival (HR of 3.2; p = 0.01 and HR of 3.0; p = 0.04) and reduced
overall survival (HR of 2.8; p = 0.04 and HR 2.9; p = 0.03). The results though refer only to the patients
that have received AR antagonists, whereas AR alteration status had no impact on the outcome after
taxane-based chemotherapy [65].
4.3.3. Mutations in DNA Damage Repair Genes as Predictive Markers to PARP Inhibitors
Based on multiple comprehensive molecular characterization analyses of advanced PCa, it was
evident that mutations in DNA damage repair genes are frequently detected in mCRPC (>10%) [66].
Following this observation, the DNA damage response (DDR) mutational status was investigated as a
predictive biomarker for treatment response in advanced PCa, such as docetaxel taxane chemotherapy,
abiraterone or enzalutamide, as well as PARP inhibition with olaparib [66]. As predicted based on the
molecular mechanisms, intervention with olaparib (PARP inhibitor) [67] in patients stratified based for
DDR mutational status (mutations in BRCA1, BRCA2, or ATM) resulted in longer progression-free
survival compared to placebo (7.4 months vs. 3.6 months; HR for progression was 0.34; p < 0.001).
Therefore, in mCPRC patients who displayed disease progression after enzalutamide or abiraterone
treatment and those stratified for DDR mutations, the use of PAPR inhibitors might be beneficial.
The molecularly driven biomarker tests, along with their clinical context of use and the targeted
omics features are summarized in Table 1. Table 1 includes a list of the commercially available tests
after obtaining approval from the FDA or certified via Clinical Laboratory Improvement Amendments
(CLIA), as a result of multiple prospective clinical studies. Moreover, as described above, this review is
focused on omics-driven biomarkers. However, in order to give a comprehensive view of the currently
commercially available tests, omics-based biomarkers that are currently measured by RT-PCR are
also listed.
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Table 1. Overview on omics-driven commercially available biomarker-based tests.
Biomarker Test Omics Features Assay Method Biofluid/Biospecimen Clinical Application References
STHLM3 nomogram
PSA, free PSA, intact PSA, KLK2, MSMB, MIC1,
232 SNPs, age, family, history, DRE
• SNPs
PSA immunoassays
+ SNP genotyping Serum
Diagnostic







Guiding 1st biopsy Van Neste et al., 2016 [32]
ExoDx Intelliscore
PCA3, ERG and SPDEF
• Exosomal mRNAs RT-PCR Urine
Diagnostic








Guiding 1st biopsy & repeated
biopsies
Hessels et al., 2003 [31];
Marks et al., 2007 [29];
Ramos et al., 2013 [30]
MiProstate
TMPRSS2-ERG and PCA3




Guiding 1st & repeated biopsies
Leyten et al., 2014 [69]
Tomlins et al., 2016 [33]
Confirm MDx
GSTP1, APC, RASSF
• Methylation Multiplex PCR Tissue (Biopsy)
Diagnostic
Guiding repeated biopsies Partin et al., 2014 [35]
OncotypeDx
12 cancer-related genes (AZGP1, KLK2, SRD5A2,
FAM13C, FLNC, GSN, TPM2, GSTM2, TPX2,






Guiding active treatment & AS
Klein et al., 2014 [46]
Cullen et al., 2015 [47]
SChLAP1
SChLAP1




treatment & AS Prensner et al., 2015 [56]
Decipher
22 coding and non-protein coding regions
• mRNAs Affymetrix microarrays Tissue
Prognostic
Monitoring metastasis
Glass et al., 2016 [42]
Ross et al., 2014 [43]
Prolaris







Leon et al., 2018 [50]
AR-V7
AR-V7




Seitz et al., 2017 [70–73]
DNA repair
genes





Response to opaparib de Bono et al., 2020 [67]
Table Abbreviations: ATM—ataxia telangiectasia-mutated gene, APC—adenomatous polyposis coli, AR-V7—androgen-receptor splice variant 7 messenger RNA, AZGP1—zinc
α 2-glycoprotein, BGN—biglycan, BRCA1—breast cancer type 1 susceptibility protein, BRCA2—breast cancer type 2 susceptibility protein, COL1A1—collagen alpha-1(I) chain,
ddPCR—droplet digital PCR, DLX1—homeobox protein DLX-1, DRE—digital rectal examination, ERG—transcriptional regulator ERG, FAM13C—protein FAM13C, FLNC—filamin-C,
GSN—gelsolin, GSTM2—glutathione S-transferase Mu 2, GSTP1—glutathione S-transferase pi gene, HOXC6—homeobox protein Hox-C6, KLK2—kallikrein-2, MIC1—macrophage
inhibitory cytokine 1, MSMB—microseminoprotein beta, PCA3—prostate cancer gene 3, PSA—prostate specific antigen, RASSF—Ras association domain-containing protein 1,
RT-PCR—reverse transcription polymerase chain reaction, SChLAP1—second chromosome locus associated with prostate-1, SFRP4—secreted frizzled-related protein 4, SNPs—single
nucleotide polymorphisms, SPDEF—SAM pointed domain-containing Ets transcription factor, SRD5A2—steroid 5 Alpha-Reductase 2, TMPRSS2—transmembrane serine protease 2,
TPM2—tropomyosin beta chain, TPX2—targeting protein for Xklp2.
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5. Omics Derived Therapeutic Targets for Advanced PCa
5.1. Integrative Omics for Personalized Drug Targeting
Cross-correlation of multiple omics datasets is expected to improve the coverage of associated
molecular pathways and thus to improve drug targeting. In such an integrative study, Drake and
colleagues [74] investigated tissue specimens from tumors derived from mCRPC patients to integrate
genomic, transcriptomic, and phosphoproteomic data for downstream pathway analysis. In this
analysis, phoshopeptides corresponding to 74 kinases were identified, 18 of which were differentially
phosphorylated in mCPRC (based on 1.5-fold threshold; adjusted p value < 0.05). Following this,
differentially expressed master transcriptional regulators, mutated genes, and differentially activated
kinases were integrated to develop a signaling network of druggable kinase pathways, characteristic
of mCRPC. Within this network, among others, signaling proteins such as DNA-dependent protein
kinase (PRKDC), 5′-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2), protein tyrosine
kinase 2 (PTK2), ribosomal protein S6 kinase alpha-4 (RPS6KA4), and cyclin-dependent kinase (CDK)
family members were defined as druggable targets in mCRPC. Using MSigDB hallmark gene sets,
six major signaling pathways were significantly enriched in mCRPC based on the phosphorylation
status of key proteins as derived by the phosphoproteomics datasets. Enriched cancer hallmarks
included among others: (a) The cell cycle pathway, (b) the DNA repair pathway, (c) AKT/mTOR/MAPK
pathway, and (d) the nuclear receptor pathway. Importantly, by building an hierarchical kinase
network, input from each patient could be imported and based on the aim to reverse as many altered
disease specific molecular features as possible, the hierarchy based network reveals the top kinase
targets for every individual patient based on connectivity scores [74].
5.2. Omics-Driven Potential Drug Targets and Downstream Omics Profiling
Starting from evaluation of patients′ genomics datasets, miR-195 was identified as an oncogene
regulator implicated in malignant tumors [75]. In advanced PCa, miR-195 downregulation was
significantly correlated with future metastasis (p < 0.001), and biochemical recurrence (p < 0.001) and
an independent predictor for recurrence free survival (RFS; p = 0.022). Further preclinical verification
confirmed the tumor suppressive role of miR-195 in PCa cell invasion, migration, and apoptosis assays
in vitro [75]. Subsequent downstream mass spectrometry proteomics analysis revealed ribosomal
protein S6 kinase B1 (RPS6KB1) as a novel direct target of miR-195. Following this observation,
knockdown of RPS6KB1 could rescue the effects induced by miR-195, with matrix metallopeptidase 9
(MMP-9), vascular endothelial growth factor (VEGF), BCL2 associated agonist of cell death (BAD),
and E-cadherin (CDH1) being downstream effectors of the miR-195-RPS6KB1 axis [75]. These results
suggest a potential of miR-195 as a target for intervention in advanced PCa.
Following the observation that SPOP is frequently mutated in advanced PCa, further investigations
were initiated to elucidate the functional implications of SPOP alterations [76]. The SPOP gene
encodes the E3 ubiquitin ligase substrate-binding adaptor speckle-type POZ protein, which binds to
bromodomain and extra-Terminal motif (BET) proteins [such as bromodomain-containing protein 2
(BRD2, BRD3, and BRD4) and as a result, leads to ubiquitination and proteasomal degradation of the
above proteins. Following this observation, downstream transcriptomics and BRD4 cistrome analyses
for identifying cis-acting targets at genome-wide scale were performed. Based on these analyses, it was
demonstrated that SPOP mutation enhances BRD4-dependent expression of GTPase Ras-related C3
botulinum toxin substrate 1 (RAC1), cholesterol biosynthesis genes, and AKT-mTORC1 activation.
Moreover, SPOP mutation promotes BET inhibitor resistance, and this effect can be reversed by AKT
inhibitors, suggesting a role of SPOP (the presence of mutated gene) as a biomarker to stratify PCa
patients towards treatment with BET inhibitors [76].
As a follow-up to genomics data analysis leading to the observation that AR is overexpressed
and hyperactivated in CRPC (via not yet exactly defined mechanisms), further investigations were
performed to reveal the molecular pathways that lead to AR amplification [77]. As a result, in a study
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targeting retinoid acid receptor-related orphan receptor γ (ROR-γ) was found overexpressed in tumors
from mCRPC patients. Additional in vitro experiments and downstream gene expression analysis
revealed that ROR-γ exerts an antagonist effect on AR function. Following this, ROR-γ-selective
antagonists (SR2211, XY018, and XY011) were applied and subsequently blocked the expression of AR
variants such as AR-V7 as well as full-length AR at the gene transcriptional level, proposing ROR-γ as
a potential drug target to overcome resistance to ADT therapy [77].
6. Conclusions
PCa is a highly heterogeneous malignancy, with advanced PCa still being a lethal disease.
The increasing number and quality of omics derived datasets available enable a better molecular
characterization of the prostate cancer underlying pathology. Based on comprehensive molecular
analysis, several gene fusions, mostly concerning AR regulated genes, along with point mutations in
oncogenes and tumor suppressor genes were revealed at an enhanced level when comparing primary
to metastatic disease. Interestingly altered pathways, involving mutations in DNA damage repair
genes frequently present in metastatic tumors were also implicated. Following up on this observation,
novel treatment schemes involving PAPR inhibitors were investigated as alternative treatments in
patients who progressed after abiraterone or enzalutamide treatment. In this setting, DDR mutational
status is investigated as a biomarker tool to stratify patients eligible for treatment with PARP inhibitors.
Complementary to this observation, molecularly driven prognostic biomarkers are of high
importance in guiding patient management, particularly for monitoring recurrence/progression to
CRPC and metastatic disease and guiding treatment in advanced PCa. Based on the retrieved studies
from this systematic review, several prognostic biomarkers were identified as a follow-up to large omics
data investigation and integration, including, among others, altered transcripts, non-coding genes
(lncRNA, miRNAs) and proteins, with higher performance reported for combination of biomarkers into
multi-parametric panels and/or by using algorithms or nomograms to additionally integrate clinical
and other variables. Additionally, omics-derived predictive biomarkers, including, among others,
results from large prospective clinical trials, demonstrate an additional potential for guiding first and
second line treatment based on prediction of response to taxane-based chemotherapy, abiraterone and
enzalutamide, and more recently, by stratifying mCRPC patients based on DDR mutational status
for PARP inhibition. A summary of the most promising omics-driven biomarkers and their clinical
potential in advanced PCa is depicted in Figure 3.
Based on this systematic search, it is evident that most omics-driven biomarkers and potential
drug targets for advanced PCa, are based on genomics and/or proteomics rather than metabolomics.
Following the selection criteria within this systematic literature search, although in the initial selection
metabolomics studies were included (n = 21), this further prioritization procedure did not result in the
final selection of publications based on metabolomics analysis. In particular, the above studies included
results based on comparisons between PCa patients and healthy controls (or patients presenting with
BPH; 14 studies), thus they were excluded. Additionally, seven studies reported experiments in cell lines
without any verification phase for the biomarkers in human specimens and were also not selected for this
review. As omics technologies are emerging and have already reached analytical maturity, the field is
evolving towards multi-omics integration, on the one hand to develop multi-omics biomarkers, but also
to suggest individualized intervention based on, e.g., druggable kinases. The multiple studies reported
provide a very good background for the application of omics-driven biomarkers and novel therapeutic
targets towards personalized medicine approaches in PCa management. This holds a substantial
promise to support tailored treatment strategies, particularly for advanced PCa, where timing is crucial.
It will now be important to achieve the transition from the multiple discovery studies, as reported
here, to testing in appropriately powered prospective clinical trials, followed by implementation in
patient management [78,79]. Unfortunately, funding for such efforts is scarce and frequently refused
based on arguments like “lack of novelty”. Overall, the currently available data clearly indicate a
potential benefit of the application of omics-based biomarkers in the management of PCa, especially in
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the context of personalized intervention. It is to be hoped that opportunities for thoroughly assessing
this potential in properly powered clinical studies will be generated, despite the lack of interest of
public funders, possibly via the inclusion of patient support groups.
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diagnosis of advanced PCa, first line treatment is initiated. (A) Omics-driven biomarkers with
prognostic value can inform patients for risk of developing progression and/or metastasis. (B) After
progression to metastatic disease, second line therapeutic options are available, including, among others,
taxane-based chemotherapy, androgen receptor inhibition, and targeted therapy by recently approved
Poly (ADP-ribose) polymerase inhibitors. In this setting, omics biomarkers to predict response to the
different therapies are of value. (C) Nevertheless, as only part of mCRPC patients respond to these
available therapies, novel drug targets based on omics derived molecular profiles are also expected
to impact decision making in advanced PCa. Abbreviations: ARIs, Androgen receptor inhibitors;
BM, bi marker; mCRPC, metastatic castration resistant prostate cancer; PARPi, Poly (ADP-ribose)
polymerase inhibitors.
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Abbre iations
ACTN1: actinin alpha 1, ADT: androgen deprivation therapy, APC: adenomatous polyposis coli, AR: androgen
receptor, AR-V: androgen-rec ptor splice variant, ATM: ataxia telangiectasia-mutated gene, AUC: area under
the curve, AURKA: aurora kinase A, AZGP1: zinc α 2-glycoprotein, BAD: BCL2 associated agonist of cell
death, BCR: biochemical recurrence, BET: bromodomain and extra-Terminal motif proteins, BGN: biglycan,
BRCA1: breast cancer type 1 susceptibility protein, BRCA2: breast cancer type 2 susceptibility protein, BRD2:
bromodomain-containing protein 2, BRD3: bromodomain-containing protein 3, BRD4: bromodomain-containing
protein 4, C4B: complement C4B, CDH1: E-cadherin, CDK: cyclin-dependent kinase, CDK12: cyclin-dependent
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kinase 12, CDKN2A: cyclin-dependent kinase inhibitor 2A, CFAP44: cilia and flagella associated protein 44,
cfDNA: cell-free DNA, CHD1: chromodomain helicase DNA binding protein 1, CHEK2: checkpoint kinase
2, CLIA: clinical laboratory improvement amendments, COL1A1: collagen alpha-1(I) chain, CT: computed
tomography, CTCs: circulating tumour cells, CUL2: cullin 2, ddPCR: droplet digital PCR, DERL1: derlin 1,
DLX1: homeobox protein DLX-1, DNMT3B: DNA (cytosine-5-)-methyltransferase 3 beta, DRE: digital rectal
examination, E2F1: E2F1 transcription factor, ETV: ETS variant transcription factor, ERG: ETS-related gene, ETS:
erythroblast transformation-specific, FAM13C: protein FAM13C, FANCA: fanconi anaemia, complementation
group A, FDA: U.S. food and drug administration, FL1: follicular lymphoma susceptibility to 1, FLNC: filamin-C,
FOXA1: forkhead Box A1, FUS: fusion RNA-binding protein FUS/TLS, GS: gleason score, GSN: gelsolin, GSTM2:
glutathione S-transferase Mu 2, GSTP1: glutathione S-transferase pi gene, HIF3A: hypoxia-inducible factor 3
alpha, HOXC6: homeobox protein Hox-C6, HSPA9: mitochondrial 70kDa heat shock protein, HR: hazard ratio,
IDH1: isocitrate dehydrogenase 1, KLK2: kallikrein-2, lncRNA: long non-coding RNA, mCRPC: metastatic
castration resistant prostate cancer, MIC1: macrophage inhibitory cytokine 1, miRNA: microRNA, MLH1: mutL
homolog 1, MMP9: matrix metallopeptidase 9, MRI: magnetic resonance imaging, MSH2: mutS homolog, MSMB:
microseminoprotein beta, MYCN: N-Myc proto-oncogene, ncRNA: noncoding RNA, NEAT: nuclear enriched
abundant transcript 1, NEPC: neuroendocrine prostate cancer, NKX3-1: homeobox protein Nkx-3.1, NUCKS1:
nuclear ubiquitous casein and cyclin-dependent kinases substrate, OR: odds ratio, OS: overall survival, PALB2:
partner and localizer of BRCA2, PARP: poly(adenosine diphosphate-ribose) polymerase, PCa: prostate cancer;
PCA3: prostate cancer gene 3, PCAT1: prostate cancer associated transcript 1, PCAT14: prostate cancer associated
transcript 14, PCGEM1: prostate-specific transcript 1, PDSS2: decaprenyl-diphosphate synthase subunit 2, PDX1:
pancreatic and duodenal homeobox 1, PI3KCA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
alpha, PLAG1: zinc finger protein PLAG1, PRKAA2: 5’-AMP-activated protein kinase catalytic subunit alpha-2,
PRKDC: DNA-dependent protein kinase, PRNCR1: prostate cancer associated non-coding RNA 1, pS6: phospho-S6
ribosomal protein, PSA: prostate specific antigen, PSMA PET-CT: antigen prostate-specific membrane antigen
imaging positron emission tomography, PTEN: phosphatase and tensin homolog, PTK2: protein tyrosine kinase 2,
RAC1: Ras-related C3 botulinum toxin substrate 1, RASSF: Ras association domain-containing protein 1, RB1:
retinoblastoma protein 1, REST: RE1 silencing transcription factor, ROR-γ: retinoid acid receptor-related orphan
receptor γ, RP: radical prostatectomy, RPS6KA4: ribosomal protein S6 kinase alpha-4, RPBS6KB1: ribosomal
protein S6 kinase B1, RT-PCR: reverse transcription polymerase chain reaction, SCGB3A1: secretoglobin family 3A
member 1, SChLAP1: second chromosome locus associated with prostate-1, SCPC: small cell prostate carcinoma,
SFRP4: secreted frizzled-related protein 4, SLC45A3: solute carrier family 45 member 3, SMAD2: mothers against
decapentaplegic homolog 2, SMAD4: mothers against decapentaplegic homolog 4, snoRNAs: small nucleolar
RNAs, SNPs: single nucleotide polymorphisms, SPDEF: SAM pointed domain-containing Ets transcription factor,
SPOP: speckle type BTB/POZ protein coding gene, SRD5A2: steroid 5 Alpha-Reductase 2, SRRM4: serine/arginine
repetitive matrix 4, TCGA: the cancer genome atlas, TMPRSS2: transmembrane serine protease 2, TP53: tumor
protein p53, TPM2: tropomyosin beta chain, TPX2: targeting protein for Xklp2, TROP2: tumor-associated calcium
signal transducer 2, VDAC1: voltage-dependent anion-selective channel 1, VEGF: vascular endothelial growth
factor, YBX1: Y box binding protein 1.
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